Dr. Said Sebti's team at VCU Massey Cancer Center made a groundbreaking discovery, developing a therapy targeting the KRAS protein in deadly cancers.Collaborating with top cancer centers, they discovered potent KRAS Binder-456, inhibiting resistant pancreatic tumors in mice. Further testing includes combining KRB-456 with standard treatments.This offers hope for innovative interventions.